Orthofix Medical (NASDAQ:OFIX) Share Price Crosses Above 200-Day Moving Average – Should You Sell?

Shares of Orthofix Medical Inc. (NASDAQ:OFIXGet Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $15.03 and traded as high as $16.31. Orthofix Medical shares last traded at $16.18, with a volume of 174,052 shares trading hands.

Orthofix Medical Trading Down 0.1 %

The company’s 50-day moving average is $16.17 and its 200 day moving average is $15.05. The company has a current ratio of 2.48, a quick ratio of 1.13 and a debt-to-equity ratio of 0.24. The firm has a market cap of $624.16 million, a PE ratio of -5.13 and a beta of 1.05.

Orthofix Medical (NASDAQ:OFIXGet Free Report) last issued its earnings results on Tuesday, August 6th. The medical device company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.58). The business had revenue of $198.62 million during the quarter, compared to analyst estimates of $195.75 million. Orthofix Medical had a negative return on equity of 20.68% and a negative net margin of 15.61%. As a group, sell-side analysts predict that Orthofix Medical Inc. will post -2.13 EPS for the current year.

Institutional Trading of Orthofix Medical

Institutional investors have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY increased its stake in Orthofix Medical by 31.3% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after buying an additional 609,137 shares during the period. Engine Capital Management LP raised its holdings in shares of Orthofix Medical by 11.0% during the second quarter. Engine Capital Management LP now owns 3,368,665 shares of the medical device company’s stock worth $44,668,000 after acquiring an additional 333,364 shares in the last quarter. Marshall Wace LLP acquired a new stake in Orthofix Medical during the second quarter valued at $2,193,000. AYAL Capital Advisors Ltd boosted its position in Orthofix Medical by 10.2% during the second quarter. AYAL Capital Advisors Ltd now owns 686,794 shares of the medical device company’s stock valued at $9,107,000 after purchasing an additional 63,697 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Orthofix Medical in the first quarter valued at about $921,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

About Orthofix Medical

(Get Free Report)

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

Further Reading

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.